# Celgenyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celgenyx

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.celgenyxbio.com
- Total disclosed funding: $14M
- Latest round: Series A (Oct 24, 2022)
- Investors on record: 1

## About

Established in 2020 and based in Hangzhou, China, Hangzhou Gelgenyx Gene Technology Co., Ltd., dba Celgenyx, operates as a biotechnology company that focuses on the treatment of malignant tumors. The company cooperates with USA in March 2020. In July 2025, Celgenyx raised an undisclosed amount of venture funding from new investor WinDigital Capital.

The company provides gene technology and cellular immune products. Its R&D platform includes hybridoma antibody technology platform, antibody humanization technology platform and human antibody phage display platform. Hybridoma antibody technology platform develops innovative murine scFv against human tumor antigen.

## Funding rounds

- Series A, Oct 24, 2022, $14M — Vivo Capital

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A